Omeros (OMER) OMS721 Shows Compelling Activity, Cowen Says

August 18, 2015 8:57 AM EDT
Get Alerts OMER Hot Sheet
Price: $5.30 --0%

Rating Summary:
    9 Buy, 3 Hold, 2 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 19 | Down: 11 | New: 19
Trade Now! 
Join SI Premium – FREE

Cowen analyst Yatin Suneja reiterated an Outperform rating on Omeros Corp. (NASDAQ: OMER) after OMS721 shows compelling activity.

Suneja commented, "OMER reported additional Ph. II data on OMS721. All 3 aHUS patients treated with ‘721 showed normalization of platelet counts and improvement in disease activity across TMA disease markers, including one patient who remains dialysis-free. In our view these data, though come from only 3 patients, are compelling and show that ‘721 could potentially have a role in aHUS."

For an analyst ratings summary and ratings history on Omeros Corp. click here. For more ratings news on Omeros Corp. click here.

Shares of Omeros Corp. closed at $14.55 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Cowen & Co